Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TAMBOCOR vs CARDRASE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class Ic antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractoriness in cardiac tissues.
CARDRASE is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
Treatment of documented life-threatening ventricular arrhythmias (e.g., sustained ventricular tachycardia),Suppression of symptomatic atrial fibrillation/flutter (off-label)
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Acute gouty arthritis,Primary dysmenorrhea
For atrial fibrillation/flutter: 50 mg orally every 12 hours; may increase by 50 mg every 4 days up to 300 mg/day. For life-threatening ventricular arrhythmias: 100 mg orally every 12 hours; increase by 50 mg every 4 days up to 400 mg/day.
Adult: 100 mg orally twice daily.
Terminal elimination half-life: 12–27 hours (mean 20 hours); prolonged to 58 hours in heart failure or renal impairment (Cr Cl < 35 m L/min).
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Hepatic metabolism via CYP2D6; active metabolite; renal excretion of unchanged drug and metabolites.
Hepatic metabolism primarily via CYP2C9, with minor contributions from CYP3A4 and CYP2C8. Metabolites are inactive and excreted renally.
Renal: 85% (30% unchanged, 55% as inactive metabolites); Fecal: 5%; Biliary: negligible.
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugate (10-20%); biliary/fecal elimination accounts for 10-15%.
90–95% bound to albumin and alpha-1-acid glycoprotein.
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
8–10 L/kg; extensive tissue distribution (lung, heart, liver).
0.2-0.3 L/kg, indicating limited distribution into tissues, consistent with high plasma protein binding.
Oral: 85–90% (first-pass metabolism minimal).
Oral bioavailability is 80-90% with modest first-pass metabolism; intravenous administration yields 100% bioavailability.
Cr Cl >50 m L/min: no adjustment; Cr Cl 35-50 m L/min: 50 mg every 12 hours; Cr Cl <35 m L/min: 100 mg every 24 hours or 50 mg every 12 hours with caution.
GFR ≥60 m L/min: No adjustment. GFR 30-59 m L/min: 100 mg once daily. GFR 15-29 m L/min: 50 mg once daily. GFR <15 m L/min: Not recommended.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 25-50%; Child-Pugh class C: contraindicated or use with extreme caution.
Child-Pugh A: No adjustment. Child-Pugh B: 50 mg once daily. Child-Pugh C: Not recommended.
Dosing not established; limited data: 1-3 mg/kg/day orally divided every 8-12 hours; maximum 6 mg/kg/day.
Children ≥1 year: 2 mg/kg orally twice daily, up to a maximum of 100 mg/dose.
Start at 50 mg every 12 hours; increase slowly with close monitoring of plasma levels and ECG; consider lower doses due to reduced renal function.
Initial dose of 50 mg once daily; may increase to 100 mg once daily based on tolerability.
May increase mortality in patients with structural heart disease (e.g., post-MI, cardiomyopathy). Reserved for life-threatening arrhythmias.
Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. Contraindicated for treatment of perioperative pain in coronary artery bypass graft surgery.
Proarrhythmic effects including new or worsened ventricular arrhythmias,Use caution in patients with conduction abnormalities (e.g., SA node dysfunction, bundle branch block),Heart failure exacerbation due to negative inotropic effects,Electrolyte disturbances (hypokalemia, hypomagnesemia) should be corrected,Plasma monitoring recommended due to narrow therapeutic index
Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, anaphylactoid reactions, serious skin reactions, hematologic toxicity, hepatic impairment, asthma exacerbation, and use in pregnancy (avoid in later stages).
Second- or third-degree AV block (unless pacemaker in place),Bifascicular block or distal conduction blocks,Cardiogenic shock or severe hypotension,Pre-existing prolonged QT interval,History of ventricular arrhythmias associated with structural heart disease
Hypersensitivity to CARDRASE or any NSAID; history of asthma, urticaria, or allergic-type reactions after aspirin or NSAIDs; perioperative pain in CABG surgery; advanced renal disease; severe hepatic impairment; active peptic ulcer or GI bleeding; third trimester of pregnancy; patients with known sulfonamide allergy (if applicable).
Grapefruit juice increases flecainide AUC by 15-40% and should be avoided. High-fat meals may delay absorption but do not significantly alter overall exposure. No other specific dietary restrictions.
Avoid high-sodium foods to reduce fluid retention. Limit intake of potassium-rich foods if hyperkalemia is a risk. Grapefruit juice may increase drug levels; avoid concurrent use.
FDA Pregnancy Category C. Flecainide crosses the placenta. First trimester: Limited human data; animal studies show fetal toxicity at maternally toxic doses. Second and third trimesters: Risk of fetal arrhythmia, including tachycardia or heart block; may require fetal echocardiography. Avoid in pregnancy unless benefit outweighs risk.
First trimester: Potential for increased risk of major malformations based on animal studies; human data insufficient. Second trimester: No specific fetal risks identified. Third trimester: Risk of neonatal hypoglycemia, hypotonia, and respiratory depression with maternal use near term.
Flecainide is excreted into breast milk. Milk-to-plasma ratio approximately 2.5 (range 1.4–3.8). Infant exposure estimated at 3–5% of maternal weight-adjusted dose. Monitor infant for bradycardia, arrhythmia, and feeding difficulties. Use with caution; alternative agents preferred.
Limited data; drug is excreted in breast milk. M/P ratio unknown. Avoid breastfeeding during therapy due to potential adverse effects in the infant.
Increased plasma volume and renal clearance in pregnancy may reduce flecainide levels. Monitor therapeutic drug levels and ECG; dose adjustments may be needed (typically increased dose required). Titrate based on arrhythmia control and toxicity. Postpartum: dose may need reduction as clearance normalizes.
Increased renal clearance during pregnancy may require 20-30% dose escalation in second and third trimesters. Monitor therapeutic drug levels to maintain efficacy. Consider dose reduction postpartum.
Tambocor (flecainide) is a class Ic antiarrhythmic used for life-threatening ventricular arrhythmias and paroxysmal atrial fibrillation/flutter. It has a narrow therapeutic index and requires ECG monitoring for QRS prolongation (>140 ms) or new arrhythmias. Contraindicated in ischemic heart disease due to increased mortality (CAST trial). Adjust dose in renal impairment (Cr Cl < 50 m L/min: start at 50 mg q12h). Proarrhythmic risk is highest in patients with structural heart disease or reduced EF. Monitor trough levels (therapeutic range: 0.2-1.0 mcg/m L).
CARDRASE (carbonic anhydrase inhibitor) may cause metabolic acidosis; monitor serum bicarbonate. Contraindicated in cirrhosis due to risk of hepatic encephalopathy. Can cause hypokalemia; check electrolytes. Adjust dose in renal impairment (Cr Cl <30 m L/min).
Take exactly as prescribed; do not stop or change dose without consulting your doctor.,Report any new or worsening chest pain, palpitations, fainting, or difficulty breathing immediately.,Avoid grapefruit juice as it can increase flecainide levels and risk of side effects.,Take with or without food; maintain consistent timing to keep levels stable.,Do not crush or chew extended-release capsules; swallow whole.
Take with food to reduce gastrointestinal upset.,Drink plenty of fluids to prevent kidney stones.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report unexplained bruising or bleeding, as it may indicate thrombocytopenia.,Do not drive or operate machinery until you know how this medication affects you, as dizziness or drowsiness can occur.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TAMBOCOR vs CARDRASE, answered by our medical review team.
TAMBOCOR is a Antiarrhythmic Agent that works by Class Ic antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractoriness in cardiac tissues.. CARDRASE is a Antiarrhythmic Agent that works by CARDRASE is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TAMBOCOR and CARDRASE depend on the specific clinical indication. These are both Antiarrhythmic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TAMBOCOR is: For atrial fibrillation/flutter: 50 mg orally every 12 hours; may increase by 50 mg every 4 days up to 300 mg/day. For life-threatening ventricular arrhythmias: 100 mg orally every 12 hours; increase by 50 mg every 4 days up to 400 mg/day.. The standard adult dose of CARDRASE is: Adult: 100 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TAMBOCOR and CARDRASE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TAMBOCOR is classified as Category C. FDA Pregnancy Category C. Flecainide crosses the placenta. First trimester: Limited human data; animal studies show fetal toxicity at maternally toxic doses. Second and third trime. CARDRASE is classified as Category C. First trimester: Potential for increased risk of major malformations based on animal studies; human data insufficient. Second trimester: No specific fetal risks identified. Third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.